Such a great time with these phenomenal fellows. Was honored to be the only community thoracic oncologist to provide a unique perspective. @integrishealth@OncLive
Thank you fellows, faculty, and OncLive for an outstanding day of learning, collaboration, and networking. Inspiring discussions, new connections, and a shared commitment to advancing care. The future is bright! @OncLive@StephenVLiu@drshieldsmd@PatelOncology
Spent over 40 minutes on the phone with a patient’s insurance because they denied her chemoIO because they misread the note for “small cell” instead of “non-small cell carcinoma”. They then realized this mistake on their end (after I pointed this out), but they couldn’t resolve it without a peer to peer.. which can’t happen until next week
🫁 𝟮𝟬 𝗣𝗼𝘀𝘁𝘀 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱𝗻’𝘁 𝗠𝗶𝘀𝘀 𝗙𝗿𝗼𝗺 𝗧𝗲𝘅𝗮𝘀 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟲
OncoDaily Lung followed the key conversations from Texas Lung Cancer Conference 2026 and gathered 20 standout posts from experts across thoracic oncology.
🔹 What stood out
• Important clinical debates
• New research perspectives
• Expert insights from leading voices
• Real discussions shaping lung cancer care
🔬 From stage III NSCLC and adjuvant therapy updates to small cell lung cancer and multidisciplinary decision-making, this meeting reflected where the field is moving next.
📌 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗽𝗼𝘀𝘁𝘀 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗯𝘆 𝗢𝗻𝗰𝗼𝗗𝗮𝗶𝗹𝘆 𝗟𝘂𝗻𝗴.
https://t.co/5i9Jg2mG7l
@DrewMoghanaki@JoeChangMD@heidi_onda@BenCreelan@lungoncdoc@jennifermarksmd@NarjustFlorezMD@chulkimMD@BalazsHalmosMD@ipreeshagul@KCargillMDPhD@ClayReedMD@yajur_arya@Latinamd@StephenVLiu@drshieldsmd
#LungCancer #TLC #NSCLC #OncoDaily #Oncology #cancer
Laura Linney powerfully capping off a phenomenal day @TLCconference. Physicians, researchers, industry, patients, and others coming together to advance lung cancer care for our patients #TexasLung26
@chulkimMD did an incredible job kicking us off today at @binaytara#OKTO26 covering perioperative treatment and importance of pCR. Several @NIH heme/onc fellow alumni here today in OKC!
ADCs are reshaping the Tx landscape in NSCLC
• Activity across multiple targets (HER2, MET, TROP2)
• Variable correlation between target expression and efficacy
Can ADCs replace docetaxel in 2L?
Yes - but better target selection & ADC design needed.
@FawziAbuRous#OKTO26
A mighty debate about the utility of ctDNA between @aadel_chaudhuri and @AminNassarMD at the @binaytara 2026 OK Thoracic oncology conference. Awesome (and entertaining debate)
Looking forward to an amazing thoracic oncology conference tomorrow in OKC with @binaytara. We have phenomenal speakers from across the country coming to OKC!